Leerink Partners analyst Daina Graybosch upgrades Summit Therapeutics (NASDAQ:SMMT) from Underperform to Market Perform and raises the price target from $12 to $13.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.